A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

PURPOSE: To characterize safety and tolerability of the selective PI3Kβ inhibitor AZD8186, identify a recommended phase II dose (RP2D), and assess preliminary efficacy in combination with abiraterone acetate or vistusertib. PATIENTS AND METHODS: This phase I open-label study included patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Choudhury, Atish D., Higano, Celestia S., de Bono, Johann S., Cook, Natalie, Rathkopf, Dana E., Wisinski, Kari B., Martin-Liberal, Juan, Linch, Mark, Heath, Elisabeth I., Baird, Richard D., García-Carbacho, Javier, Quintela-Fandino, Miguel, Barry, Simon T., de Bruin, Elza C., Colebrook, Steve, Hawkins, George, Klinowska, Teresa, Maroj, Brijesh, Moorthy, Ganesh, Mortimer, Peter G., Moschetta, Michele, Nikolaou, Myria, Sainsbury, Liz, Shapiro, Geoffrey I., Siu, Lillian L., Hansen, Aaron R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662946/
https://www.ncbi.nlm.nih.gov/pubmed/35247924
http://dx.doi.org/10.1158/1078-0432.CCR-21-3087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662946/
https://www.ncbi.nlm.nih.gov/pubmed/35247924
http://dx.doi.org/10.1158/1078-0432.CCR-21-3087

Ejemplares similares